Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to compare the immune function and infection mechanism of patients with hematologic tumors and those people without underlying diseases after infection with SARS-CoV-2. Clinical characteristics, treatment options and responses will be collected. Peripheral blood will be collected from patients with hematologic tumors infected with SARS-CoV-2 and those people without underlying diseases infected with SARS-CoV-2.

Detailed Description
-----------------
To establish a retrospective and prospective cohort of patients with hematologic tumors infected with SARS-CoV-2 and people without underlying diseases infected with SARS-CoV-2. Firstly, peripheral blood samples will be collected at infection time points and after SARS-CoV-2 nucleic acid testing turns negative. Subsequently, the transcriptome sequencing and immunological experiments will be performed to analyze the differentially expressed genes, immune function of cells, etc. Comparative analysis: To compare the immune function of patients with hematologic tumors and those without underlying diseases after infection with SARS-CoV-2. The transcriptomic and proteomic changes of patients with hematologic tumors are compared with those without underlying diseases after infection with SARS-CoV-2. From the perspective of complex (human protein interaction subnetwork), the dynamic change process of SARS-CoV-2-targeted human protein complex (periodic complex) was deeply explored, in order to further analyze its potential dynamic infection mechanism and provide new clues for the discovery of drug targets.

Official Title
-----------------
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors and Discovery of Potential Drug Targets

Conditions
-----------------
SARS-CoV-2 Infection, Hematologic Malignancy

Intervention / Treatment
-----------------
* Other: None intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Clinical diagnosis of hematologic tumors Clinical diagnosis of SARS-CoV-2 infection Exclusion Criteria: - Severe diseases associated with other systems

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with SARS-CoV-2 positive hematologic tumors<br>Patients with SARS-CoV-2 positive hematologic tumors over 18 years old excluding patients with severe diseases associated with other systems. | Other: None intervention<br>* None intervention.<br>|
| People with SARS-CoV-2 positive without underlying diseases<br>People with SARS-CoV-2 positive without underlying diseases over 18 years old excluding people with severe diseases associated with other systems. | Other: None intervention<br>* None intervention.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors | To compare the infection mechanism and immune function of patients with hematologic tumors infected with SARS-CoV-2 and people infected with SARS-CoV-2 without underlying diseases. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS-CoV-2 infection, hematologic malignancy, leukemia, interaction, immune function, network analysis